221 related articles for article (PubMed ID: 17956584)
1. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency.
Kallenberg CG
Clin Exp Immunol; 2007 Dec; 150(3):437-41. PubMed ID: 17956584
[TBL] [Abstract][Full Text] [Related]
2. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
3. Redimune NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions.
Piguet D; Tosi C; Lüthi JM; Andresen I; Juge O;
Clin Exp Immunol; 2008 Apr; 152(1):45-9. PubMed ID: 18241226
[TBL] [Abstract][Full Text] [Related]
4. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.
Martin A; Lavoie L; Goetghebeur M; Schellenberg R
Transfus Med; 2013 Feb; 23(1):55-60. PubMed ID: 23167310
[TBL] [Abstract][Full Text] [Related]
5. Kiovig for primary immunodeficiency: reduced infusion and decreased costs per infusion.
Connolly M; Simoens S
Int Immunopharmacol; 2011 Sep; 11(9):1358-61. PubMed ID: 21570491
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form.
Mahieu AC; Sisti AM; Joekes S; Manfredi MJ
Allergol Immunopathol (Madr); 2006; 34(6):242-7. PubMed ID: 17173840
[TBL] [Abstract][Full Text] [Related]
7. Why I use subcutaneous immunoglobulin (SCIG).
Shapiro RS
J Clin Immunol; 2013 Jan; 33 Suppl 2():S95-8. PubMed ID: 23264027
[TBL] [Abstract][Full Text] [Related]
8. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
McCormack PL
BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
[TBL] [Abstract][Full Text] [Related]
9. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
Günther G; Dreger B
Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
[TBL] [Abstract][Full Text] [Related]
10. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID).
Viallard JF; Brion JP; Malphettes M; Durieu I; Gardembas M; Schleinitz N; Hoarau C; Lazaro E; Puget S
Rev Med Interne; 2017 Sep; 38(9):578-584. PubMed ID: 28683953
[TBL] [Abstract][Full Text] [Related]
11. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states.
Tcheurekdjian H; Martin J; Kobayashi R; Wasserman R; Hostoffer R
Allergy Asthma Proc; 2006; 27(6):532-6. PubMed ID: 17176791
[TBL] [Abstract][Full Text] [Related]
12. Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia.
Spadaro G; Vultaggio A; Alberto Bosi A; Reichert D; Janssen J; Lamacchia D; Nappi L; Pecoraro A; Milito C; Ferraro A; Matucci A; Bacchiarri F; Carrai V; Hibbeler A; Speckman E; Guarnieri C; Bongiovanni S; Quinti I
Int Immunopharmacol; 2017 Mar; 44():38-42. PubMed ID: 28073042
[TBL] [Abstract][Full Text] [Related]
13. An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease.
Kriván G; Königs Ch; Bernatowska E; Salama A; Wartenberg-Demand A; Sonnenburg C; Linde R
Vox Sang; 2015 Oct; 109(3):248-56. PubMed ID: 25953213
[TBL] [Abstract][Full Text] [Related]
14. Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study.
Nobre FA; Gonzalez IG; Simão RM; de Moraes Pinto MI; Costa-Carvalho BT
BMC Immunol; 2014 Jun; 15():26. PubMed ID: 24952415
[TBL] [Abstract][Full Text] [Related]
15. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.
Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O
J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500
[TBL] [Abstract][Full Text] [Related]
16. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.
Esmaeilzadeh H; Askarisarvestani A; Hosseini N; Samimi S; Shafiei A; Mahdaviani SA; Eslami N; Chavoshzadeh Z; Fallahi M; Khakbazanfard N; Shabestari MS; Aleyasin S; Nabavizadeh SH; Cheraghi T; Kalantari A; Ahmadiafshar A; Safari M; Eslamian MH; Molatefi R; Shirkani A; Heidarzadeh Arani M; Tavakol M; Bemanian MH; Arshi S; Nabavi M; Shokri S; Shahhosseini B; Mortazavi N; Nakhaei P; Nazari F; Fallahpour M; Ahanchian H; Moazzen N; Khoshkhui M; Motlagh AV; Aghamohammadi A; Abolhassani H; Yazdani R; Rezaei N
Clin Immunol; 2021 Sep; 230():108826. PubMed ID: 34418548
[TBL] [Abstract][Full Text] [Related]
17. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and kinetics of a solvent-detergent-treated intravenous immunoglobulin preparation in hypogammaglobulinaemia patients.
Ebeling F; Baer M; Hormila P; Järventie G; Koistinen P; Kätkä K; Oksanen K; Perkkiö M; Ruutu T; Soppi E
Vox Sang; 1995; 69(2):91-4. PubMed ID: 8585206
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
